论文部分内容阅读
本文旨在评价澳化异丙托品联合舒喘灵对稳定性慢性阻塞性肺病（COPD）患者的扩张支气管作用是否优于单纯使用汉化异丙托品。26例稳定性COPD患者的平均FEVl0．87上0．32L。所有患者隔天进行下列其中一种治疗；（1）鼻吸入澳化异丙托品40Ng，I组2（2）鼻吸溪化异丙托品80＃g，H组
This article aims to evaluate whether the combination of ipratropium and salbutamol is superior to bronchodilator alone in patients with stable chronic obstructive pulmonary disease (COPD). Twenty-six patients with stable COPD had an average FEV 0.87 of 0.32L. All patients underwent one of the following treatments every other day: (1) nasal inhalation of 40Ng ipratropium, group I, 2 (2)